These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 12138330)

  • 1. Investigation of the anti-HIV properties of oxihumate.
    van Rensburg CE; Dekker J; Weis R; Smith TL; Janse van Rensburg E; Schneider J
    Chemotherapy; 2002 Jul; 48(3):138-43. PubMed ID: 12138330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the immunostimulatory properties of oxihumate.
    Jooné GK; Dekker J; van Rensburg CE
    Z Naturforsch C J Biosci; 2003; 58(3-4):263-7. PubMed ID: 12710739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of HIV-1 in cell culture by synthetic humate analogues derived from hydroquinone: mechanism of inhibition.
    Schneider J; Weis R; Männer C; Kary B; Werner A; Seubert BJ; Riede UN
    Virology; 1996 Apr; 218(2):389-95. PubMed ID: 8610466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.
    Szabó J; Cervenák L; Tóth FD; Prohászka Z; Horváth L; Kerekes K; Beck Z; Bácsi A; Erdei A; Peerschke EI; Füst G; Ghebrehiwet B
    Clin Immunol; 2001 May; 99(2):222-31. PubMed ID: 11318594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
    Garcia-Perez J; Staropoli I; Azoulay S; Heinrich JT; Cascajero A; Colin P; Lortat-Jacob H; Arenzana-Seisdedos F; Alcami J; Kellenberger E; Lagane B
    Retrovirology; 2015 Jun; 12():50. PubMed ID: 26081316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humic acids from oxidized coals I. Elemental composition, titration curves, heavy metals in HA samples, nuclear magnetic resonance spectra of HAs and infrared spectroscopy.
    Kurková M; Klika Z; Kliková C; Havel J
    Chemosphere; 2004 Feb; 54(8):1237-45. PubMed ID: 14664853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A broad spectrum anti-HIV inhibitor significantly disturbs V1/V2 domain rearrangements of HIV-1 gp120 and inhibits virus entry.
    Berinyuy E; Soliman ME
    J Recept Signal Transduct Res; 2016; 36(2):119-29. PubMed ID: 26446906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
    Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
    Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico design of novel broad anti-HIV-1 agents based on glycosphingolipid β-galactosylceramide, a high-affinity receptor for the envelope gp120 V3 loop.
    Andrianov AM; Kornoushenko YV; Kashyn IA; Kisel MA; Tuzikov AV
    J Biomol Struct Dyn; 2015; 33(5):1051-66. PubMed ID: 24942968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: potential applications for preventing HIV-1 infection.
    Yang J; Li L; Tan S; Jin H; Qiu J; Mao Q; Li R; Xia C; Jiang ZH; Jiang S; Liu S
    Fitoterapia; 2012 Mar; 83(2):348-55. PubMed ID: 22155187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically stable vanadium(IV) porphyrins as a new class of anti-HIV agents.
    Wong SY; Wai-Yin Sun R; Chung NP; Lin CL; Che CM
    Chem Commun (Camb); 2005 Jul; (28):3544-6. PubMed ID: 16010318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
    Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
    N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HIV-1 activity of low molecular weight sulfated chitooligosaccharides.
    Artan M; Karadeniz F; Karagozlu MZ; Kim MM; Kim SK
    Carbohydr Res; 2010 Mar; 345(5):656-62. PubMed ID: 20117763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HIV activity of semisynthetic derivatives of andrographolide and computational study of HIV-1 gp120 protein binding.
    Uttekar MM; Das T; Pawar RS; Bhandari B; Menon V; Nutan ; Gupta SK; Bhat SV
    Eur J Med Chem; 2012 Oct; 56():368-74. PubMed ID: 22858223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the in vitro activities of ammonium humate and of enzymically oxidized chlorogenic and caffeic acids against type 1 and type 2 human herpes virus (author's transl)].
    Thiel KD; Helbig B; Klöcking R; Wutzler P; Sprössig M; Schweizer H
    Pharmazie; 1981; 36(1):50-3. PubMed ID: 6261267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment.
    de Larrañaga GF; Wingeyer SD; Puga LM; Alonso BS; Benetucci JA
    Eur J Clin Microbiol Infect Dis; 2006 Feb; 25(2):98-103. PubMed ID: 16477441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
    Hamza A; Zhan CG
    J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs--modern Trojan horses to combat HIV.
    Ramana LN; Sharma S; Sethuraman S; Ranga U; Krishnan UM
    Eur J Pharm Biopharm; 2015 Jan; 89():300-11. PubMed ID: 25500283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.